Bladder Preservation Therapy: A Review of the Literature and Future Directions

      Trimodal bladder preservation therapy (ie, transurethral resection followed by chemoradiotherapy) may be an acceptable treatment alternative to radical cystectomy with urinary diversion in the carefully selected patient with muscle invasive bladder cancer. Although no head-to-head randomized controlled trials have been performed, large retrospective cohort reviews and observational data analyses suggest comparable oncologic outcomes in select patients with the additional benefit of maximizing quality of life and maintaining the patient's native bladder. In this review, we discuss the evolution and clinical outcomes of bladder preservation therapy, highlighting its role in the contemporary management of muscle invasive bladder cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Cancer Society
        Cancer Facts and Figures 2016.
        American Cancer Society, Atlanta2016
        • Prout G.R.
        • Marshall V.F.
        The prognosis with untreated bladder tumors.
        Cancer. 1956; 9: 551-558
        • Fedeli U.
        • Fedewa S.A.
        • Ward E.M.
        Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007.
        J Urol. 2011; 185: 72-78
        • Shabsigh A.
        • Korets R.
        • Vora K.C.
        • et al.
        Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.
        Eur Urol. 2009; 55: 164-174
        • Gandaglia G.
        • Varda B.
        • Sood A.
        • et al.
        Short term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database.
        Can Urol Assoc J. 2014; 8: e681-e687
        • Shimko M.S.
        • Tollefson M.K.
        • Umbreit E.C.
        • Farmer S.A.
        • Blute M.L.
        • Frank I.
        Long-term complications of conduit urinary diversions.
        J Urol. 2011; 185: 562-567
        • Clark P.E.
        • Spiess P.E.
        • Agarwal N.
        • et al.
        NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.
        National Comprehensive Cancer Network, Inc, 2015
        • Smith Z.L.
        • Christodouleas J.P.
        • Keefe S.M.
        • Malkowicz S.B.
        • Guzzo T.J.
        Bladder preservation in the treatment of muscle-invasive bladder cancer: a review of the literature and a practical approach to therapy.
        BJU Int. 2013; 112: 13-25
        • Gakis G.
        • Efstathiou J.
        • Lerner S.P.
        • et al.
        ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
        Eur Urol. 2013; 63: 45-57
        • Biagioli M.C.
        • Fernandez D.C.
        • Spiess P.E.
        • Wilder R.B.
        Primary bladder preservation treatment for urothelial bladder cancer.
        Cancer Control. 2013; 20: 188-199
        • Pietzak E.J.
        • Sterling M.E.
        • Smith Z.L.
        • Malkowicz S.B.
        • Guzzo T.J.
        Outcomes of radical cystectomy in potential candidates for bladder preservation therapy.
        Urology. 2015; 85: 869-875
        • Volkmer B.G.
        • Kuefer R.
        • Bartsch G.
        • et al.
        Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival.
        Cancer. 2005; 104: 2384-2391
        • Solsona E.
        • Iborra I.
        • Collado A.
        • Rubio-Briones J.
        • Casanova J.
        • Calatrava A.
        Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer.
        J Urol. 2010; 184: 475-480
        • Herr H.W.
        Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.
        J Clin Oncol. 2001; 19: 89-93
        • Mak R.H.
        • Hunt D.
        • Shipley W.U.
        • et al.
        Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
        J Clin Oncol. 2014; 32: 3801-3809
        • Ploussard G.
        • Daneshmand S.
        • Efstathiou J.A.
        • et al.
        Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
        Eur Urol. 2014; 66: 120-137
        • James N.D.
        • Hussian S.A.
        • Hall E.
        • et al.
        Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
        N Engl J Med. 2012; 366: 1477-1488
        • Tarin T.V.
        • Power N.E.
        • Ehdale B.
        • et al.
        Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity.
        Eur Urol. 2012; 61: 1025-1030
        • Huddart R.A.
        • Hall E.
        • Hussain S.A.
        • et al.
        Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
        Int J Radiat Oncol Biol Phys. 2013; 87: 261-269
        • Hagan M.P.
        • Witner K.A.
        • Kaufman D.S.
        • et al.
        RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
        Int J Radiat Oncol Biol Phys. 2003; 57: 665-672
        • Kaufman D.S.
        • Winter K.A.
        • Shipley W.U.
        • et al.
        Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
        Urology. 2009; 73: 833-837
        • Mitin T.
        • Hunt D.
        • Shipley W.U.
        • et al.
        Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial.
        Lancet Oncol. 2013; 14: 863-872
        • Kaufman D.S.
        • Winter K.A.
        • Shipley W.U.
        • et al.
        The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
        Oncologist. 2000; 5: 471-476
        • Coppin C.M.
        • Gospodarowicz M.K.
        • James K.
        • et al.
        Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group.
        J Clin Oncol. 1996; 14: 2901-2907
        • Azria D.
        • Riou O.
        • Rebillard X.
        • et al.
        Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
        Int J Radiat Oncol Biol Phys. 2014; 88: 853-859
        • Tester W.
        • Caplan R.
        • Heaney J.
        • et al.
        Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
        J Clin Oncol. 1996; 14: 119-126
        • Tester W.
        • Porter A.
        • Asbell S.
        • et al.
        Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12.
        Int J Radiat Oncol Biol Phys. 1993; 25: 783-790
        • Shipley W.U.
        • Witner K.A.
        • Kaufman D.S.
        • et al.
        Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
        J Clin Oncol. 1998; 16: 3576-3583
        • Shipley W.U.
        • Prout G.R.
        • Einstein A.B.
        • et al.
        Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery.
        JAMA. 1987; 258: 931-935
        • von der Maase H.
        • Hansen S.W.
        • Roberts J.T.
        • et al.
        Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
        J Clin Oncol. 2000; 18: 3068-3077
        • Mitin T.
        • Goerge A.
        • Zietman A.L.
        • et al.
        Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: a pooled analysis of NRG oncology/RTOG 9906 and 0233.
        Int J Radiat Oncol Biol Phys. 2016; 94: 67-74
        • Stein J.P.
        • Lieskovsky G.
        • Cote R.
        • et al.
        Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients.
        J Clin Oncol. 2001; 19: 666-675
        • Grossman H.B.
        • Natale R.B.
        • Tangen C.M.
        • et al.
        Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
        N Engl J Med. 2003; 349: 859-866
        • Dalbagni G.
        • Genega E.
        • Hashibe M.
        • et al.
        Cystectomy for bladder cancer: a contemporary series.
        J Urol. 2001; 165: 1111-1116
        • Efstathiou J.A.
        • Spiegel D.Y.
        • Shipley W.U.
        • et al.
        Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
        Eur Urol. 2012; 61: 705-711
        • Gloeckler-Ries L.A.
        • Young J.L.
        • Keel G.E.
        • Eisner M.P.
        • Lin Y.D.
        • Horner M.J.D.
        SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001, patient and tumor characteristics.
        National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD2007
        • Bekelman J.E.
        • Handorf E.A.
        • Guzzo T.
        • et al.
        Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research.
        Value Health. 2013; 16: 610-618
        • Cahn D.B.
        • Handorf E.
        • Nordsiek M.
        • et al.
        Contemporary utilization trends and survival outcomes in patients undergoing radical cystectomy and bladder preservation therapy for muscle invasive bladder cancer.
        J Clin Oncol. 2016; 34 (abstr 387)
        • Karakiewics P.I.
        • Shariat S.F.
        • Palapattu G.S.
        • et al.
        Precystectomy nomogram for prediction of advanced bladder cancer stage.
        Eur Urol. 2006; 50: 1254-1260
        • Tritschler S.
        • Mosler C.
        • Tilki D.
        • Buchner A.
        • Stief C.
        • Graser A.
        Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer.
        Urology. 2012; 79: 1317-1321
        • Takayanagi A.
        • Masumori N.
        • Takahashi A.
        • Takagi Y.
        • Tsukamoto T.
        Upper urinary tract recurrence after radical cystectomy for bladder cancer: incidence and risk factors.
        Int J Urol. 2012; 19: 229-233
        • Efstathiou J.A.
        • Bae K.
        • Shipley W.U.
        • et al.
        Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
        J Clin Oncol. 2009; 27: 4055-4061
        • Zeitman A.L.
        • Sacco D.
        • Skowronski U.
        • et al.
        Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long term survivors.
        J Urol. 2003; 170: 1772-1776
        • Mathieu R.
        • Lucca I.
        • Klatte T.
        • Babjuk M.
        • Shariat S.F.
        Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?.
        Curr Opin Urol. 2015; 25: 476-482
        • Iwai A.
        • Koga F.
        • Fujii Y.
        • et al.
        Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy.
        Jpn J Clin Oncol. 2011; 41: 1373-1379
        • Ramani V.A.
        • Maddineni S.B.
        • Grey B.R.
        • Clarke N.W.
        Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis.
        Eur Urol. 2010; 57: 1058-1063
        • Eswara J.R.
        • Efstathiou J.A.
        • Heney N.M.
        • et al.
        Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.
        J Urol. 2012; 187: 463-468
        • Yoshida S.
        • Koga F.
        • Kobayashi S.
        • et al.
        Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.
        Int J Radiat Oncol Biol Phys. 2012; 83: e21-e27
        • Southwest Oncology Group
        • National Cancer Institute S1314
        Co-expression extrapolation (COXEN) program to predict chemotherapy response in patients with bladder cancer.
        in: [Internet]. National Library of Medicine (US), Bethesda, MD2000 (Available at) (Accessed April 04, 2016; Identifier: NCT02177695)
        • Knollman H.
        • Godwin J.L.
        • Jain R.
        • Wong Y.-N.
        • Plimack E.R.
        • Geynisman D.M.
        Muscle-invasive urothelial bladder cancer: an update on systemic therapy.
        Ther Adv Urol. 2015; 7: 312-330
        • Kang J.J.
        • Steinberg M.L.
        • Kupelian P.
        • Alexander S.
        • King C.R.
        Whole versus partial bladder radiation: use of an image-guided hypofractionated IMRT bladder-preservation protocol.
        Am J Clin Oncol. 2015; (epub ahead of print)
        • Sridhar S.S.
        • Shaheena B.
        • Chung P.W.M.
        • et al.
        Are we systemically under treating cisplatin-eligible patients with muscle invasive bladder cancer (MIBC) who are undergoing bladder preservation by chemoradiotherapy?.
        J Clin Oncol. 2016; 34 (abstr 417)
        • Fox Chase Cancer Center
        Trimodal bladder preservation therapy: maximal transurethral resection followed by accelerated methotraxate, vinblastine, doxorubicin, and cisplatin (AMVAC) and concurrent chemoradiation with intensity modulated radiation therapy for muscle invasive bladder cancer.
        in: [Internet]. National Library of Medicine (US), Bethesda, MD2000 (Available at) (Accessed April 04, 2016; Identifier: NCT02710734)
        • King C.R.
        • et al.
        • UCLA/Jonsson Comprehensive Cancer Center and National Cancer Institute
        Quality of life after bladder-preservation chemotherapy and radiation therapy in patients with muscle-invasive bladder cancer.
        in: [Internet]. National Library of Medicine (US), Bethesda, MD2000 (Available at) (Accessed April 04, 2016; Identifier: NCT02688348)
        • Shrivastava S.
        • Mansure J.J.
        • Almajed W.
        • et al.
        The role of HMGB1 in radioresistance of bladder cancer.
        Mol Cancer Ther. 2016; 15: 471-479
        • Desai N.B.
        • Iyer G.I.
        • Cha E.K.
        • et al.
        Deleterious alterations in dna damage response genes are associated with improved outcome in muscle-invasive bladder cancer patients treated with radiation-based bladder preservation [abstract]: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research.
        2015 (Philadelphia, PA. Cancer Res 2015;75(15 Suppl):Abstr nr 602)
        • Tsai Y.C.
        • Pei-Yin H.
        • Tzen K.Y.
        • et al.
        Synergistic blockade of EGFR and HER2 by new generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells.
        Mol Cancer Ther. 2015; 14: 810-820